Wegovy: Switching from Injection to Pill Leads to 4 kg Weight Loss in 3 Months
Novo Reveals Real-World Data at EASD
Analysis of 194 Patients Who Switched to Wegovy Pill
Ozempic Dose Increase Reduces Cardiovascular Risk by 6% Compared to Mounjaro
A study has found that patients who switched from injectable obesity treatments to oral pills lost an average of 4 kilograms more over three months. This is the first real-world data confirming the weight loss effect when switching from injections to pills in a clinical setting. Contrary to concerns that stopping injections and switching to pills would reduce effectiveness and lead to weight regain, the weight loss effect persisted.
On September 30 (local time), Novo Nordisk (hereafter Novo) released real-world data (RWD) at the 'European Association for the Study of Diabetes (EASD 2026)' regarding patients who switched from injectable obesity treatments to the oral medication Wegovy Pill (active ingredient: semaglutide). The analysis was based on records of patients who received obesity treatment prescriptions via the US telemedicine platform 'Ro'.
According to Novo, among 194 overweight or obese adults who switched from injectable semaglutide or tirzepatide (marketed as Mounjaro) to Wegovy Pill, average body weight decreased by 4.0 kilograms (4.1%) over three months. The proportion of patients who lost more than 5% of their body weight was 40.7%, and the percentage of patients with a body mass index (BMI) of 30 or higher dropped from 87.1% to 65.5%. When switching from injectable to oral medication, the patients' average body weight was 100.5 kilograms, with an average gap of 36.8 days between the last injection and the start of the pill regimen.
The study did not disclose how long patients had previously been on injectable treatments. If some switched early in their injection course, the continued trend of weight loss may have contributed to the result, while those whose weight plateaued before switching could be reflecting benefits specific to switching to the pill. The research team emphasized that this study confirmed that the weight loss effect is maintained even after switching from injections to pills.
Wegovy Pill is a once-daily oral tablet containing the same active ingredient, semaglutide, as the injectable Wegovy. In a phase 3 clinical trial involving 307 adults with obesity, patients who started treatment with 25 mg of Wegovy Pill and continued for 64 weeks reduced their body weight by an average of 13.6%. This is comparable to the 14.9% reduction recorded with the injectable Wegovy over 68 weeks in approval trials. Based on these results, the US Food and Drug Administration (FDA) approved Wegovy Pill in December last year as the first oral treatment for obesity.
Wegovy Pill does not require needles or refrigeration. Instead, it must be taken once daily on an empty stomach, and the patient should refrain from eating for 30 minutes afterward. Martin Holst Lange, head of research and development at Novo, said, "Some patients want to switch to oral medication due to anxiety about injections, lifestyle reasons, or personal preferences."
For Diabetes Patients, 'Dose Increase'... Ozempic Reduces Cardiovascular Risk by 6% Compared to Switching to Mounjaro
On September 29 (local time), Novo also presented real-world data on its type 2 diabetes treatment Ozempic (active ingredient: semaglutide) at the same conference. Analysis of US insurance claims data showed that among patients who increased their Ozempic dose from 1 mg to 2 mg (185,705 people), the risk of death, heart attack, or stroke was 6% lower compared to those who switched to Eli Lilly's Mounjaro (23,104 people). As patients consider whether to switch medications or increase the dose for blood sugar control, Novo's cardiovascular results are seen as a direct challenge to Mounjaro.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
An industry source commented, "As injectable obesity treatments become established in the market, pharmaceutical companies are now focusing their attention on formulation transition and expanding indications."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.